Australia's PBS added Dostarlimab and Difelikefalin for endometrial cancer and CKD patients on May 1, 2022.
Australia's Pharmaceutical Benefits Scheme (PBS) added two life-changing drugs from May 1, 2022: Dostarlimab (Jemperli®) for endometrial cancer patients and Difelikefalin (Korsuva®) for chronic kidney disease (CKD) patients experiencing severe itching (pruritus). Both drugs were previously unavailable under the PBS. Around 200 women with endometrial cancer and 2,800 CKD patients are expected to benefit.
May 12, 2024
3 Articles